AAVOLUTION
Dead / Abandoned — Abandoned — no statement of use filed (as of 12 Jan 2026)
What this means for you
This application is over — abandoned 12 Jan 2026. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98433745
- Mark type
- Stylized text
- Filed
- 05 Mar 2024
- Published for opposition
- 29 Oct 2024
- Abandoned
- 12 Jan 2026
- Attorney of record
- Joshua M. Gerben, Esq.
Goods and services
- Class 040 — Treatment of materials: Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals, plasmid DNA production; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting
- Class 042 — Scientific and technological services: Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research; research and development in the field of gene therapy acceleration, vector genome copy titers, droplet digital polymerase chain reaction (PCR) and digital polymerase chain reaction (PCR), mass spectrometry, capsid characterization, bioassays, plasmid DNA, and analytics testing in the field of genes and gene therapy
Owner
- CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC, King of Prussia, PA, US
- CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC, King of Prussia, PA, US
Prosecution history
- 12 Jan 2026 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 12 Jan 2026 — ABANDONMENT - NO USE STATEMENT FILED
- 17 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Apr 2025 — SOU EXTENSION 1 GRANTED
- 16 Apr 2025 — SOU EXTENSION 1 FILED
- 16 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 10 Dec 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 29 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Oct 2024 — PUBLISHED FOR OPPOSITION
- 09 Oct 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 19 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 18 Sept 2024 — ASSIGNED TO EXAMINER
- 16 Jul 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 05 Mar 2024 — NEW APPLICATION ENTERED